Pulmonology

Though new therapies are still in the distant future, advances in diagnosis may be on the horizon.

The IL-4 and -13 inhibitor antibody also reported improved outcomes in patients with comorbid asthma.

Allergic rhinitis involves the immune system, which responds to allergens by releasing histamine, causing inflammatory symptoms in the nose, throat, and eyes—which can also worsen asthma conditions.

Distinguishing pulmonary arterial hypertension in patients is a difficult early diagnosis. But seeking out a combination of unexplained symptoms is a good first step.

Results connecting breathlessness catastrophizing with reduced quality of life also have implications for populations with asthma or COPD.

Experts advise that primary care physicians give pause next time they treat a patient with unexplained dyspnea—could it be pulmonary hypertension?

The optimal treatment of submassive pulmonary embolism (PE) remains controversial, despite growing evidence to support a role for catheter-directed therapy in carefully selected patients.

Though the commonly accepted ratio is 3:1 women, longtime clinicians suggest PAH ratio is more likely closer to 4:1.

Mary Beth Scholand, MD, outlines the best treatment practices for idiopathic pulmonary fibrosis (IPF) to date and therapies worth investigating in the future.

Nicola Hanania, MD, MS, director of the Airways Clinical Research Center at Baylor College of Medicine, explains the latest research on COPD treatments and outlines how they all measure.

Previously approved in 2015, Stiolto Respimat Inhalation Spray is now indicated for the treatment of COPD including chronic bronchitis and emphysema.

The 2019 CHEST Meeting in New Orleans may be headlined by newly approved therapies including dupilumab and tezepelumab.

Using data registries from initial trials, companies such as Actelion will be looking to expand research beyond the first first or second year of care in patients with PAH.

Recent trials have evidenced that minority patient groups in particular are more likely to worsen their primary treatment adherence while embracing alternative medicine measures.

Once physicians know if it's the cause of PAH or just simply an overlap, comorbidities have to be closely monitored as disease progression.

A twice-daily 50 mcg dose of the nebulized LAMA therapy also had better results for patients with poor FEV1 compared to tiotropium.

Why delving into the symptoms of the most at-need patients is critical for care.

Clinical research has begun to distinguish biomarkers for both conditions, research has established their similarities, and therapies are becoming pathway-based. Should asthma-COPD diagnoses be necessary?

Investigators from the Nationwide Children’s Hospital assessed family history in relation to asthma control in pediatric patients.

A COPD care bundle delivered by a multidisciplinary health care team can reduce hospital readmission rates for acute exacerbations of COPD (AECOPD).

Montelukast/levocetirizine combination therapy demonstrates safety and efficacy in phase 3 clinical trial for the treatment of patients with perennial allergic rhinitis who have mild-to-moderate asthma.

Before biologics are implemented, what should physicians be doing to ensure asthma control in their patients?

The addition of a couple of new drug classes at the turn of the century have given clinicians the greenlight to stack therapies at initial treatment.

There’s a challenge to achieve control in some asthma patients since the disease is heterogenous—both allergic and non-allergic triggers can initiate Type 2 inflammatory pathways that can drive pathology.